specialist Verona Pharma has closed an oversubscribed private placement and subscription with $200m raised from existing and new investors.
Once agency fees and other expenses are dealt with, the net proceeds of the placement are estimated to be around $183m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The financing was led by new investors 鈥� RA Capital Management, Access Biotechnology, Perceptive Advisors, Acorn Bioventures, PBM Capital, Samsara BioCapital, Foresite Capital, Sphera, Fairmount and Soleus Capital. Novo Holdings, Vivo Capital and other existing investors also participated in the placement.
Commenting on this financing, Verona CEO David Zaccardelli says: 鈥淚t is great to retain this expertise and to expand on it by adding additional support from new investors who also have deep knowledge of investing in drug development.鈥�
Verona is a public company listed on Nasdaq and the London Stock Exchange鈥檚 AIM, which means it is more typical to raise funds through 鈥減rivate placements of debt or stock鈥�, rather than through series rounds, explains Zaccardelli. He adds that the company is very pleased to have raised almost four times its market capitalisation, and calls this raise 鈥渦nprecedented鈥�.
Promise of ensifentrine in COPD
Zaccardelli links the oversubscribed nature of this private placement to investors seeing 鈥渧alue in our compelling and comprehensive data package鈥� for lead product ensifentrine for COPD, compared to placebo. 鈥淎ttracting such support provides a validation of聽Verona聽Pharma鈥檚 team, strategy and the potential opportunity for ensifentrine in respiratory disease,鈥� he adds.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEnsifentrine is a first-in-class drug, which combines a bronchodilator and anti-inflammatory agent into one molecule. Verona believes it has the potential to revolutionise COPD treatment, which currently 鈥渋nvolves dual or triple therapy with long-acting muscarinic antagonists (LAMAs), long-acting beta adrenoceptor agonists (LABAs) and inhaled corticosteroids鈥�, explains Zaccardelli. Not only is this approach burdensome on the patient, the combination fails to relieve the symptoms of millions of COPD patients.
New therapeutic options are urgently needed since the estimates the incidence of COPD is growing, and the lung disease is now the third biggest killer in the world.
Verona is planning to use this $200m financing to fund Phase III trials of ensifentrine in COPD. These trials are expected to start later this year, and the funding will support the studies through to 2023. The trials will study ensifentrine as both a monotherapy and an add-on to either a LAMA or a LABA.
Zaccardelli concludes: 鈥淭he financing is a significant milestone and brings us closer to our goal of ensuring ensifentrine is available for the millions of COPD patients who urgently need better treatments.鈥�
Positive results for ensifentrine in clinical trials
Verona鈥檚 Phase III programme for ensifentrine 鈥� known as ENHANCE 鈥� is being launched on the back of very promising results for ensifentrine in a Phase II programme that involved 16 clinical trials in a total of 1,300 patients.
In a statement, Zaccardelli noted: 鈥淲e continue to be very encouraged by the Phase II results that have demonstrated ensifentrine鈥檚 effects on lung function, COPD symptoms and quality of life as well as its favourable safety profile.鈥�
Although Verona has focused on studying ensifentrine in a nebulised formulation so far 鈥� and this will be focus of the ENHANCE trials 鈥� the company recognises patients may prefer handheld inhaler formats. Therefore, it has 鈥渄eveloped formulations of ensifentrine in dry powder inhaler and pressurised metered dose inhaler formats鈥�, according to Zaccardelli.
Verona has undertaken two successful Phase II trials of both dry power inhaler and pressurised metered dose inhaler formulations of ensifentrine in the last year. Following the publication of interim results in March 2020, the second half of the pressurised metered dose formulation trial has been postponed due to the Covid-19 pandemic.
To date, there have been no announcements from Verona about progressing these two formulations into Phase III studies.
